Kwara Awewura, Herold Jacqueline S, Machan Jason T, Carter E Jane
Department of Medicine, Miriam Hospital, RISE Building, Providence, RI 02906, USA.
Chest. 2008 Apr;133(4):862-8. doi: 10.1378/chest.07-2024. Epub 2007 Dec 10.
The treatment of latent tuberculosis infection (LTBI) is essential for tuberculosis elimination in the United States, but the major limitation is poor adherence to therapy. To aid the design of targeted adherence interventions, we investigated the factors associated with noncompletion of isoniazid (INH) therapy for LTBI.
A retrospective analysis of patients with who failed to complete vs those who completed 9 months of INH therapy at the RISE TB Clinic (Miriam Hospital; Providence, RI) in 2003 was performed. Factors associated with treatment noncompletion were examined using univariate and multiple logistic regression analysis.
Of 845 patients with LTBI, 690 patients (81.6%) initiated INH therapy, of whom 426 patients (61.7%) completed therapy, and 246 patients (35.6%) were lost to follow-up. Treatment was discontinued in 18 patients (2.6%). Patients who failed to complete therapy were younger (mean age, 30.6 vs 33.8 years, respectively; p = 0.006), and were more likely to be uninsured (42.9% vs 29.8%, respectively; p = 0.0004), to be postpartum (66.7% vs 37.3%, respectively; p = 0.043), and to report treatment side effects (54.8% vs 30.1%, respectively; p < 0.0001). Reported treatment side effects (odds ratio [OR], 3.6; 95% confidence interval [CI], 2.2 to 6.2) and lack of medical insurance (OR, 1.7; 95% CI, 1.1 to 2.7) were each associated with treatment noncompletion in a model including both. Also, pregnant women were more likely than nonpregnant women to fail to initiate INH treatment (52.1% vs 14.7%, respectively; p < 0.0001).
LTBI patients who are young, pregnant or postpartum, uninsured, and/or report treatment side effects may require additional case management to improve INH treatment completion rates.
在美国,潜伏性结核感染(LTBI)的治疗对于消除结核病至关重要,但主要限制是治疗依从性差。为了辅助设计针对性的依从性干预措施,我们调查了与LTBI患者未完成异烟肼(INH)治疗相关的因素。
对2003年在RISE结核病诊所(米里亚姆医院;罗德岛州普罗维登斯)未完成9个月INH治疗的患者与完成治疗的患者进行了回顾性分析。使用单因素和多因素逻辑回归分析来检查与治疗未完成相关的因素。
在845例LTBI患者中,690例(81.6%)开始接受INH治疗,其中426例(61.7%)完成治疗,246例(35.6%)失访。18例(2.6%)患者停止治疗。未完成治疗的患者更年轻(平均年龄分别为30.6岁和33.8岁;p = 0.006),更有可能未参保(分别为42.9%和29.8%;p = 0.0004),处于产后状态(分别为66.7%和37.3%;p = 0.043),且报告有治疗副作用(分别为54.8%和30.1%;p < 0.0001)。在一个同时包含这两个因素的模型中,报告的治疗副作用(比值比[OR],3.6;95%置信区间[CI],2.2至6.2)和未参保(OR,1.7;95%CI,1.1至2.7)均与治疗未完成相关。此外,孕妇比非孕妇更有可能未开始INH治疗(分别为52.1%和14.7%;p < 0.0001)。
年轻、怀孕或产后、未参保和/或报告有治疗副作用的LTBI患者可能需要额外的病例管理,以提高INH治疗完成率。